Mingming Han, Holly Springs, NC (US); Rajesh Kumar Kainthan, Tappan, NY (US); Jin-Hwan Kim, Suffern, NY (US); and Avvari Krishna Prasad, Chapel Hill, NC (US)
Assigned to PFIZER INC., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Mar. 1, 2023, as Appl. No. 18/176,631.
Application 18/176,631 is a continuation of application No. 17/400,938, filed on Aug. 12, 2021, granted, now 11,603,384.
Application 17/400,938 is a continuation of application No. 16/923,154, filed on Jul. 8, 2020, granted, now 11,117,928, issued on Sep. 14, 2021.
Application 16/923,154 is a continuation of application No. 16/505,757, filed on Jul. 9, 2019, granted, now 10,745,438, issued on Aug. 18, 2020.
Application 16/505,757 is a continuation of application No. 14/652,723, granted, now 10,392,420, issued on Aug. 27, 2019, previously published as PCT/IB2013/060933, filed on Dec. 13, 2013.
Claims priority of provisional application 61/740,311, filed on Dec. 20, 2012.
Prior Publication US 2023/0203091 A1, Jun. 29, 2023
1. An immunogenic composition comprising a glycoconjugate comprising a S. pneumoniae serotype 12F capsular polysaccharide conjugated via an oxidized primary hydroxyl group to a carrier protein, wherein the oxidized primary hydroxyl group is present on an α-D-Glop or a 2-Glcp sugar residue of said S. pneumoniae serotype 12F capsular polysaccharide, wherein said glycoconjugate has a molecular weight of between about 500 kDa and about 5,000 kDa and a saccharide:carrier protein ratio (w/w) between 0.2 and 4, wherein the amount of free S. pneumoniae serotype 12F polysaccharide in the composition is less than about 35% free saccharide relative to total S. pneumoniae serotype 12F polysaccharide.